INTERLEUKIN GENETICS, INC. | |||||
FINANCIAL HIGHLIGHTS | |||||
Balance Sheet Data : (Unaudited) | March 31, | December 31, | |||
2011 | 2010 | ||||
Cash and cash equivalents | $ 2,841,057 | $ 3,999,029 | |||
Total current assets | $ 3,540,743 | $ 4,752,790 | |||
Total assets | $ 4,661,693 | $ 5,975,000 | |||
Total current liabilities | $ 1,495,890 | $ 1,633,096 | |||
Total liabilities | $ 12,495,890 | $ 12,633,096 | |||
Total shareholders' deficit | $ (7,834,197) | $ (6,658,096) | |||
Total liabilities and shareholders' deficit | $ 4,661,693 | $ 5,975,000 | |||
Statement of Operations Data (Unaudited): | Three Months Ended March 31, | ||||
2011 | 2010 | ||||
Revenue: | |||||
Genetic testing revenue | $ 719,447 | $ 365,911 | |||
Other | 38 | 2,799 | |||
Total revenue | 719,485 | 368,710 | |||
Cost of revenue | 357,589 | 413,407 | |||
Gross profit (loss) | 361,896 | (44,697) | |||
Operating costs and expenses: | |||||
Research and development | 304,820 | 416,996 | |||
Selling, general and administrative | 1,202,454 | 1,426,271 | |||
Amortization of intangibles | 28,863 | 28,863 | |||
Total operating expenses | 1,536,137 | 1,872,130 | |||
Loss from operations | (1,174,241) | (1,916,827) | |||
Total other income and (expense), net | (81,470) | (66,307) | |||
Loss before income taxes | (1,255,711) | (1,983,134) | |||
Income taxes | - | - | |||
Net loss | $ (1,255,711) | $ (1,983,134) | |||
Basic and diluted net loss per common share | $ (0.03) | $ (0.06) | |||
Weighted average common shares outstanding, | |||||
basic and diluted | 36,618,010 | 33,139,173 | |||
